Search Videos by Topic or Participant
Browse by Series:

Managing Renal Pelvis Transitional Cell Carcinoma

Insights From: Dean F. Bajorin, MD, MSKCC; Daniel P. Petrylak, MD, Yale;Evan Y. Yu, MD, Seattle Cancer Care
Published: Thursday, Apr 23, 2015
For High-Definition, Click
The treatment of patients with renal pelvic tumors includes cystectomy and in high-risk disease potentially adjuvant chemotherapy, says Dean F. Bajorin, MD. Condcuting a nephroureterectomy, which results in the laparoscopic removal of the renal pelvis, kidney, bladder cuff, and the entire ureter, reduces an individual’s renal function by half but can improve outcomes. However, this approach results in a loss of opportunity to administer cisplatin-based therapy, explains Bajorin.

For patients with renal pelvic tumors, Evan Y. Yu, MD, suggests that prefers to enroll individuals into a clinical trial if available, rather than pursue immediate treatment. Outside of the clinical trial setting and surgery, there is a lack of clear definitive data suggesting an optimal approach. Ongoing clinical studies are assessing whether neoadjuvant chemotherapy confers survival benefit in this patient population.

A phase II study is assessing gemcitabine plus cisplatin as neoadjuvant therapy for patients with high-grade upper tract urothelial carcinoma, Bajorin notes. The study will assess time to progression and overall survival at 3 years as a secondary endpoint with the primary outcome measure focused on pathologic response rates (NCT01261728).
Slider Left
Slider Right
For High-Definition, Click
The treatment of patients with renal pelvic tumors includes cystectomy and in high-risk disease potentially adjuvant chemotherapy, says Dean F. Bajorin, MD. Condcuting a nephroureterectomy, which results in the laparoscopic removal of the renal pelvis, kidney, bladder cuff, and the entire ureter, reduces an individual’s renal function by half but can improve outcomes. However, this approach results in a loss of opportunity to administer cisplatin-based therapy, explains Bajorin.

For patients with renal pelvic tumors, Evan Y. Yu, MD, suggests that prefers to enroll individuals into a clinical trial if available, rather than pursue immediate treatment. Outside of the clinical trial setting and surgery, there is a lack of clear definitive data suggesting an optimal approach. Ongoing clinical studies are assessing whether neoadjuvant chemotherapy confers survival benefit in this patient population.

A phase II study is assessing gemcitabine plus cisplatin as neoadjuvant therapy for patients with high-grade upper tract urothelial carcinoma, Bajorin notes. The study will assess time to progression and overall survival at 3 years as a secondary endpoint with the primary outcome measure focused on pathologic response rates (NCT01261728).
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x